WO2026103722 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI)
National phase entry is expected:
Publication Number
WO/2026/103722
Publication Date
21.05.2026
International Application No.
PCT/CN2025/134281
International Filing Date
12.11.2025
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI)
[French]
COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DU FACTEUR XI DE COAGULATION (FXI)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
Priority Data
PCT/CN2024/131711
13.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4504 | |
| EPO | Filing, Examination, Granting | 69025 | |
| Japan | Filing, Examination, Granting | 4151 | |
| South Korea | Filing, Examination, Granting | 6076 | |
| USA | Filing, Examination, Granting | 20240 |
Total:
103,996
Contact Us
Abstract[English]
Compositions and methods useful for inhibiting the expression of Plasma Coagulation Factor XI (FXI) gene and for treating FXI-associated diseases and conditions are provided. Also provided are FXI dsRNA agents, FXI antisense polynucleotide agents, compositions comprising FXI dsRNA agents, and compositions comprising FXI antisense polynucleotide agents that can be used to inhibit FXI expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour inhiber l'expression du gène du facteur XI de coagulation (FXI) plasmatique et pour traiter les maladies et affections associées au FXI. La présente invention concerne également des agents ARNdb FXI, des agents polynucléotidiques antisens FXI, des compositions comprenant des agents ARNdb FXI et des compositions comprenant des agents polynucléotidiques antisens FXI qui peuvent être utilisés pour inhiber l'expression du FXI dans des cellules et chez des sujets.